Phathom Pharmaceuticals (PHAT) Change in Receivables (2023 - 2026)

Phathom Pharmaceuticals (PHAT) has 4 years of Change in Receivables data on file, last reported at $2.6 million in Q1 2026.

• On a quarterly basis, Change in Receivables rose 206.7% year-over-year to $2.6 million in Q1 2026; TTM through Mar 2026 was $44.4 million, a 36.56% increase from a year earlier, with the FY2025 full-year figure at $39.3 million, up 5.84% from the prior year.
• Change in Receivables for Q1 2026 stood at $2.6 million, down from $22.3 million in the prior quarter.
• Over the last five years, Change in Receivables for PHAT reached as high as $22.3 million in Q4 2025 and fell as low as -$2.4 million in Q1 2025.
• Historically, Change in Receivables has averaged $8.1 million across 4 years, with a median of $5.8 million in 2024.
• Across the five-year window, Change in Receivables soared 984.0% in 2024 and slumped 208.47% in 2025, its largest moves.
• Year by year, Change in Receivables stood at $1.6 million in 2023, then surged by 984.0% to $17.7 million in 2024, then climbed by 25.89% to $22.3 million in 2025, then plunged by 88.38% to $2.6 million in 2026.
• Per Business Quant data, the three most recent Change in Receivables figures were $2.6 million in Q1 2026, $22.3 million in Q4 2025, and $4.5 million in Q3 2025.